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Expression of MCL-1 is frequently elevated in cancer and is implicated in the resistance to chemotherapy by
the BCL-2 small molecule inhibitor ABT-737. A recent paper in Nature identified USP9X as an antagonist of
MCL-1 ubiquitinylation and degradation. Often upregulated in tumor cells, USP9X activity influences the
response to ABT-737.The intricate decision processes that
dictate cell life and death frequently con-
verge on the BCL-2 family of proteins
that control mitochondrial outer mem-
brane integrity and the mitochondrial
pathway of apoptosis (Letai, 2008). One
family member, antiapoptotic myeloid
cell leukemia sequence 1 (MCL-1), is an
essential survival factor for stem and
progenitor cells of multiple cellular line-
ages, and its overexpression is common
in human cancers, including B cell and
mantle cell lymphomas, acute lympho-
blastic leukemia, chronic myelogenous
leukemia, chronic lymphocytic leukemia,
and multiple myeloma. High expression
of MCL-1 correlates with chemothera-
peutic resistance and disease progres-
sion, although, unlike BCL-2, chromo-
somal translocations have not been
implicated in dysregulating MCL-1 levels.
Instead, cellular signaling regulates
MCL-1 function and expression at the
posttranslational level and aberrations insignaling lead to elevation of MCL-1 in
human cancer. Although posttranslational
modifications are known in other BCL-2
family members, MCL-1 is unique in its
short half-life, partly because of regulated
ubiquitinylation and proteasomal degra-
dation. Cancer cells often violate cellular
checkpoints that should induce apo-
ptosis, leading to the hypothesis that
cancer cells are ‘‘addicted’’ to antiapop-
totic BCL-2 family members that support
their survival under adverse conditions.
ABT-737, a small-molecule inhibitor of
BCL-2, BCL-XL, and BCL-w, promotes
apoptosis in some cancer cells. However,
high MCL-1 expression renders cancer
cells resistant to ABT-737; thus, MCL-1
expression represents a critical resis-
tance mechanism to ABT-737 efficacy.
Recently, a new player in the control of
MCL-1 stability was identified: ubiquitin
specific peptidase 9 X-linked (USP9X)
(Schwickart et al., 2010). Deubiquitinases
(DUBs) are proteins that act to removeconjugated ubiquitin, thereby antago-
nizing the effect of ubiquitin E3 ligases.
RNAi-mediated silencing of USP9X re-
sulted in loss of MCL-1 without affecting
its mRNA expression (see Figure 1). Bio-
chemically, USP9X binds to MCL-1 and
directly removes degradative Lys-48-
linked polyubiquitin chains on the protein.
Intriguingly, high levels of MCL-1 corre-
lated with elevated USP9X expression
in follicular lymphoma, ductal adeno-
carcinoma, colon adenocarcinoma, and
small-cell lung carcinoma samples. Fur-
thermore, increased expression of USP9X
mRNA significantly associated with poor
prognosis in a retrospective study of
multiple myeloma samples. For deter-
mining whether the interaction between
USP9X and MCL-1 might affect ABT-737
sensitivity, USP9X was silenced by RNAi
in a panel of ABT-737-resistant tumor cell
lines. Loss of USP9X expression reduced
MCL-1 levels in these cell lines and
increased their sensitivity to ABT-737.February 17, 2010 ª2010 Elsevier Inc. 117
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Figure 1. The Regulation of MCL-1 Protein Levels
MCL-1 associates with a DUB, USP9X, which counters the effects of MULE and other E3 ubiquitin ligases
and reduces proteasome-dependent degradation of the antiapoptotic protein. GSK3 phosphorylates
MCL-1, promotes its dissociation from USP9X, and thereby increases ubiquitinylation and decreases
its half-life. MCL-1 translation is regulated by mTOR, which can also be inhibited by GSK3, and thus
inhibition of GSK3 elevates MCL-1 levels in two ways (via increased translation and half-life). Knockdown
of USPX9 dramatically promotes loss of MCL-1, leading to the speculation that USPX9 may not only
decrease half-life but also production of MCL-1.
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signaling represents a critical control
point for regulating MCL-1. Phosphoryla-
tion of Ser-159 on human MCL-1 by
GSK3 promotes MCL-1 degradation by
a proteasome-dependent mechanism
(Ding et al., 2007; Maurer et al., 2006).
Strikingly, mutation of these three resi-
dues to alanine (blocking phosphoryla-
tion) enhanced the interaction between
USP9X and MCL-1 and increased MCL-1
protein levels, whereas mutation of
these residues to aspartic acid (phospho-
mimic) decreased the interaction and
decreased the steady-state level of
MCL-1. Furthermore, cellular stress such
as UV irradiation disrupted the interaction
between MCL-1 and USP9X, enhancing
MCL-1 turnover. Treatment of UV-irradi-
ated cells with a GSK3 inhibitor main-
tained the interaction between MCL-1
and USP9X and stabilized MCL-1.
The control of MCL-1 protein levels is
critical to our understanding of normal
and cancer biology (Figure 1). Two E3
ligases have been implicated in
promoting MCL-1 turnover. The first,
MCL-1-ubiquitinating ligase E3 (MULE),
a HECT-domain (homologous to the118 Cancer Cell 17, February 17, 2010 ª2010E6-AP carboxyl-terminus) E3 ligase,
possesses a BH3 domain, similar to that
of proapoptotic BAK, that allows it to
target MCL-1. Interestingly, although
RNAi-mediated silencing of MULE slows
MCL-1 turnover, degradation neverthe-
less occurs, suggesting that additional
pathways foster MCL-1 elimination
(Zhong et al., 2005). The other E3 ligase,
Skp1/Cul1/F-box protein b-transducin
repeat-containing protein (SCFb-TrCP),
requires MCL-1 phosphorylation by
GSK3 at Ser-159 for mediating recogni-
tion (Ding et al., 2007). In contrast to
MULE, the interaction between b-TrCP
and MCL-1 is facilitated by phosphoryla-
tion of the same serine and threonine resi-
dues that Schwickart and colleagues
identified to be potentially recognized by
USP9X. Thus, the possibility exists that
b-TrCP and USP9X might compete for
MCL-1 binding. Although both MULE
and b-TrCP can target MCL-1 for degra-
dation, neither is MCL-1 specific as they
have been implicated in ubiquitinylating
a myriad of substrates. The relative contri-
butions of these or other unidentified
MCL-1-specific E3 ligases in regulating
MCL-1 remain unclear.Elsevier Inc.Although to date there are no reported
genetic models for loss of MULE or
b-TrCP, RNAi-mediated silencing of either
does not completely block MCL-1 elimina-
tion (Zhong, et al., 2005; Ding, et al., 2007).
Furthermore, although MCL-1 is clearly
ubiquitinylated in cells, mutagenesis of the
lysine residues required for ubiquitinylation
slows, but does not block, MCL-1 elimina-
tion (Zhong et al., 2005). In contrast, block-
ing proteasome function appears to have
a much stronger effect in blocking MCL-1
elimination, leading to the possibility that
additional factors or pathways may exist
to regulate MCL-1 stability (Maurer et al.,
2006; Nijhawan et al., 2003). One possibility
is that additional interacting proteins, regu-
lated by ubiquitinylation, may affect the
degradation of MCL-1. Interactions with
BH3-only family members have been impli-
cated in modulating MCL-1 expression;
NOXA has been proposed to promote
MCL-1 degradation and BIM has been
implicated in stabilizing MCL-1 protein
(Czabotar et al., 2007). The mechanism by
which BH3-only molecules act to regulate
MCL-1 expression is unclear, but may be
at the level of competition with MULE
(Zhong et al., 2005). Additionally, it is
possible that MCL-1 may undergo protea-
some-dependent, but ubiquitinylation-
independent, degradation as has been
identified for an expanding number of
proteins (Hoyt and Coffino, 2004).
Although RNAi-mediated silencing of
USP9X led to dramatic changes in
steady-state MCL-1 protein levels, kinetic
assays indicated that a loss of USP9X had
only minor effects on the half-life of MCL-1
(i.e., 17 versus 9 min). Given that MCL-1
mRNA levels were unaffected by gain or
loss of USP9X, the effects of this DUB on
MCL-1 are presumably dictated by the
rates of translation and degradation. Little
is known, however, about the control
of MCL-1 translation. In an AKT-driven,
Em-Myc lymphoma mouse model, transla-
tional regulation of MCL-1 by mTOR has
been implicated in promoting lymphoma-
genesis (Mills et al., 2008). Given that
GSK3 inhibits mTOR, it remains possible
that pharmacologic blockade of GSK3
activity not only increases the stability of
MCL-1 but also its translation.
This leads to an intriguing speculation.
Might there be other targets of USP9X
that affect the translation of MCL-1,
thereby influencing accumulation of the
protein not only in terms of its stability
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dent for such an effect comes from the
control of TP53 levels by its E3 ligase,
MDM2. In addition to controlling the
stability of TP53, MDM2 targets a ribo-
somal protein, L26, which is important in
regulating the rate of TP53 translation
through interactions in the 30 UTR of the
mRNA (Ofir-Rosenfeld et al., 2008).
Thus, regulation of MDM2 function has
effects on TP53 protein levels that are
independent of the interaction of MDM2
with TP53 protein itself. Might ubiquitina-
tion-de-ubiquitination events similarly
affect the translation of MCL-1? If so,
then changes in the expression of
USP9X might produce important ‘‘off-
target’’ effects on MCL-1 levels through
multiple, integrated mechanisms. The
combination of a slightly increased half-life and a decreased rate of translation
will lead to a more complete loss of
MCL-1 (as observed upon knock-down
of USP9X) than would the direct effect
on half-life alone. This might help to
account for how small changes in the
half-life of MCL-1 correlate with dramatic
changes in MCL-1 levels, through the
functions of this fascinating DUB.
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